Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1369949 | Bioorganic & Medicinal Chemistry Letters | 2012 | 6 Pages |
Abstract
From an initial lead 1, a structure-based design approach led to identification of a novel, high-affinity iminohydantoin BACE1 inhibitor that lowers CNS-derived Aβ following oral administration to rats. Herein we report SAR development in the S3 and F′ subsites of BACE1 for this series, the synthetic approaches employed in this effort, and in vivo data for the optimized compound.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Jared N. Cumming, Elizabeth M. Smith, Lingyan Wang, Jeffrey Misiaszek, James Durkin, Jianping Pan, Ulrich Iserloh, Yusheng Wu, Zhaoning Zhu, Corey Strickland, Johannes Voigt, Xia Chen, Matthew E. Kennedy, Reshma Kuvelkar, Lynn A. Hyde, Kathleen Cox,